학술논문
Dysbiosis in Takayasu arteritis complicated with infectious endocarditis following tocilizumab administration.
Document Type
Article
Source
Subject
*TAKAYASU arteritis
*DYSBIOSIS
*TOCILIZUMAB
*
*
Language
ISSN
0300-9742
Abstract
Approximately 60% of patients with Takayasu arteritis (TAK) relapse; in such patients, the use of biologics is critical to reduce the corticosteroid dose ([1], [2]). Special attention should be paid when TCZ is used in TAK patients with a history of vascular surgery because of the risk of IE. Although no biologics met the primary endpoint for a randomized control trial in TAK, tocilizumab (TCZ) administration showed a favourable time to relapse in the TAKT study ([3]). [Extracted from the article]